港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

劲方医药-B

31.360

-0.640-2.00%

成交量：35.26万

成交额：1,112.52万

市值：116.03亿

市盈率：-15.87

高：32.280

开：32.020

低：30.800

收：32.000

52周最高：50.200

52周最低：24.320

股本：3.70亿

香港流通股本：3.38亿

量比：0.30

换手率：0.10%

股息：- -

股息率：- -

每股收益(LYR):-1.976

净资产收益率：--

总资产收益率：-30.27%

市净率：-4.02

市盈率(LYR):-15.87

市销率: 54.85

数据加载中...

总览公司新闻资讯公告

劲方医药-B10月10日遭主力抛售118.2万元

【IPO追踪】充电桩赛道龙头来了！挚达科技首日暴涨超180%

劲方医药-B10月09日主力净流出863.7万元散户资金买入

“全球新”推动“全球化”！从“药谷首家”到“数量翻倍”，浦东生物医药迎来“上市潮”

劲方医药-B10月02日获主力加仓622.1万元

劲方医药-B：2025 年中期报告

香港交易所

浦东生物医药企业竞逐“全球新”

劲方医药-B(02595)分子胶Pan RAS(ON)抑制剂GFH276治疗RAS突变型癌症患者的I/II期临床试验首位患者完成入组

国信证券-医药生物行业周报（25年第36周）：劲方医药在港交所上市

劲方医药-B09月25日主力净流出839.0万元散户资金买入

劲方医药涨超11%公司研究数据亮相AACR年会目前已形成RAS靶向疗法矩阵

异动解读 | 劲方医药-B盘中大涨10.92%，股东转仓4.37亿港元或提振信心

劲方医药-B(02595)股东将股票由中信证券经纪香港转入渣打银行(香港) 转仓市值4.37亿港元

一图解码：港股IPO一周回顾 11家公司递表劲方医药上市后股价震荡

上市次日跌逾6%仍获“惜售”，劲方医药-B(02595)何以成创新药牛市“新宠”？

9月14-20日港股IPO观察：11家递表、3家上市，奇瑞汽车募资火爆

上市公司网

近期国内融资|劲方医药港股上市，爱科百发和新元素医院IPO申请

劲方医药-B09月22日主力净流出40.0万元散户资金买入

新药周观点：劲方医药IPO上市 KRAS G12D进展值得关注

被3000亿资金哄抢的创新药企，上市首日暴涨110%

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/02595/news?page=2"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02595","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02595\",,,,,undefined,":{"symbol":"02595","market":"HK","secType":"STK","nameCN":"劲方医药-B","latestPrice":31.36,"timestamp":1763366893755,"preClose":32,"halted":0,"volume":352600,"delay":0,"floatShares":338000000,"shares":370000000,"eps":-1.976,"marketStatus":"未开盘","change":-0.64,"latestTime":"11-17 16:08:13","open":32.02,"high":32.28,"low":30.8,"amount":11125210,"amplitude":0.04625,"askPrice":31.48,"askSize":1800,"bidPrice":31.36,"bidSize":2200,"shortable":0,"etf":0,"ttmEps":-2.744,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1763429400000},"marketStatusCode":0,"adr":0,"listingDate":1758211200000,"exchange":"SEHK","adjPreClose":32,"openAndCloseTimeList":[[1763343000000,1763352000000],[1763355600000,1763366400000]],"volumeRatio":0.30164,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02595\",,,,,undefined,":{"symbol":"02595","floatShares":338000000,"roa":"-30.27%","roe":"--","lyrEps":-1.976,"volumeRatio":0.30164,"shares":370000000,"dividePrice":0,"high":32.28,"amplitude":0.04625,"preClose":32,"low":30.8,"week52Low":24.32,"pbRate":"-4.02","psRate":"54.85","week52High":50.2,"institutionHeld":0,"latestPrice":31.36,"committee":0.1,"eps":-1.976,"divideRate":0,"volume":352600,"delay":0,"ttmEps":-2.744,"open":32.02,"prevYearClose":20.39,"prevWeekClose":32,"prevMonthClose":27.32,"prevQuarterClose":40,"fiveDayClose":29.24,"twentyDayClose":31.8,"sixtyDayClose":20.39},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02595\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02595\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02595\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02595\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02595","date":"2025-11-14","current":-11.428571,"percent":0.405405,"low":-19.62221,"twenty":-18.558233,"median":-10.712517,"eighty":-9.936062,"high":-9.058573,"avg":-12.958612,"sd":3.82741,"marketCap":11851732160},"quantilePoints":[{"date":"2025-09-19","current":-19.62221,"twenty":-19.62221,"median":-19.62221,"eighty":-19.62221,"marketCap":14538840523},{"date":"2025-09-26","current":-17.850791,"twenty":-18.989349,"median":-18.569255,"eighty":-18.336187,"marketCap":13192012066},{"date":"2025-10-03","current":-19.06699,"twenty":-19.162092,"median":-18.845312,"eighty":-18.417026,"marketCap":14124431767},{"date":"2025-10-10","current":-11.809112,"twenty":-19.045684,"median":-18.645404,"eighty":-16.087956,"marketCap":11948785798},{"date":"2025-10-17","current":-10.861917,"twenty":-19.006201,"median":-18.336187,"eighty":-11.374297,"marketCap":10981832034},{"date":"2025-10-24","current":-9.567304,"twenty":-18.816504,"median":-12.899451,"eighty":-10.554523,"marketCap":9676444452},{"date":"2025-10-31","current":-9.989391,"twenty":-18.681528,"median":-11.762498,"eighty":-10.081819,"marketCap":10118416331},{"date":"2025-11-07","current":-9.878556,"twenty":-18.646705,"median":-10.725216,"eighty":-9.89625,"marketCap":9999899010},{"date":"2025-11-14","current":-11.674836,"twenty":-18.558233,"median":-10.712517,"eighty":-9.936062,"marketCap":11851732160}],"updateTime":1763397858541},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02595\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2574487483","title":"劲方医药-B10月10日遭主力抛售118.2万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2574487483","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574487483?lang=zh_cn&edition=fundamental","pubTime":"2025-10-10 16:15","pubTimestamp":1760084149,"startTime":"0","endTime":"0","summary":"10月10日, 劲方医药-B股价跌4.42%，报收34.60元，成交金额4217.3万元，换手率0.37%，振幅11.44%，量比1.21。劲方医药-B今日主力资金净流出118.2万元，上一交易日主力净流出863.7万元。该股近5个交易日下跌17.46%，主力资金累计净流出117.7万元；近20日主力资金累计净流出1941.5万元，其中净流出天数为7日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101016210697264c5d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101016210697264c5d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1515","02595","09939","BK1574"],"gpt_icon":0},{"id":"2574410021","title":"【IPO追踪】充电桩赛道龙头来了！挚达科技首日暴涨超180%","url":"https://stock-news.laohu8.com/highlight/detail?id=2574410021","media":"IPO解码","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574410021?lang=zh_cn&edition=fundamental","pubTime":"2025-10-10 14:05","pubTimestamp":1760076309,"startTime":"0","endTime":"0","summary":"而在10月10日，又有金叶国际集团、挚达科技两只新股同时上市，且都在首日迎来暴涨。其中，挚达科技出现高开大涨，截至发稿时间已飙升超180%，市值超过了110亿港元整数关口。此外，国际配售方面，挚达科技获2.37倍认购，国际发售股份最终数目为538.10万股股份，相当于发售股份总数的90%。根据弗若斯特沙利文的资料，2022年至2024年及2025年前三个月，按家用电动汽车充电桩销量计，挚达科技的中国市场份额达13.6%，全球市场份额达到9.0%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251010140948a6b2a6fc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251010140948a6b2a6fc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02595","HSTECH","02583","02650"],"gpt_icon":1},{"id":"2574016660","title":"劲方医药-B10月09日主力净流出863.7万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2574016660","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574016660?lang=zh_cn&edition=fundamental","pubTime":"2025-10-09 16:15","pubTimestamp":1759997734,"startTime":"0","endTime":"0","summary":"10月09日, 劲方医药-B股价跌8.22%，报收36.20元，成交金额7915.2万元，换手率0.65%，振幅9.43%，量比2.84。劲方医药-B今日主力资金净流出863.7万元，上一交易日主力净流入129.7万元。该股近5个交易日下跌9.45%，主力资金累计净流入622.6万元；近20日主力资金累计净流出1823.3万元，其中净流出天数为6日。该股主力净额占比0.07%，港股市场排名2539/2673。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202510091621099724e17d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202510091621099724e17d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09939","BK1161","BK1515","BK1574","02595"],"gpt_icon":0},{"id":"2574661153","title":"“全球新”推动“全球化”！从“药谷首家”到“数量翻倍”，浦东生物医药迎来“上市潮”","url":"https://stock-news.laohu8.com/highlight/detail?id=2574661153","media":"浦东发布","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574661153?lang=zh_cn&edition=fundamental","pubTime":"2025-10-09 09:45","pubTimestamp":1759974355,"startTime":"0","endTime":"0","summary":"从2018年君实生物成为“张江药谷”首家港股18A上市企业后，浦东生物医药企业赴港上市“热潮”汹涌，“厚积薄发”的浦东生物医药产业正迎来从“量变”走向“质变”，成为“价值金矿”。“全球新”推动“全球化”“差异化”获得市场高估值我国创新药虽然高速发展，但一些领域也存在跟随创新多、同质化严重、临床价值优势不明显等问题。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251009103408a6b155d3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251009103408a6b155d3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02595","01877","BK1583","BK1574","09939","BK1515","06978","BK1161"],"gpt_icon":0},{"id":"2572957691","title":"劲方医药-B10月02日获主力加仓622.1万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2572957691","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572957691?lang=zh_cn&edition=fundamental","pubTime":"2025-10-02 16:15","pubTimestamp":1759392932,"startTime":"0","endTime":"0","summary":"10月02日, 劲方医药-B股价涨4.80%，报收41.92元，成交金额5112.2万元，换手率0.38%，振幅5.75%，量比0.62。劲方医药-B今日主力资金净流入622.1万元，上一交易日主力净流入38.9万元。该股近5个交易日上涨3.15%，主力资金累计净流出816.3万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流出1823.8万元，其中净流出天数为5日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025100216174194b84857&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025100216174194b84857&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","09939","BK1515","02595"],"gpt_icon":0},{"id":"2571411443","title":"劲方医药-B：2025 年中期报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2571411443","media":"香港交易所","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571411443?lang=zh_cn&edition=fundamental","pubTime":"2025-09-30 18:42","pubTimestamp":1759228931,"startTime":"0","endTime":"0","summary":"牛牛AI助手已提取核心信息劲方医药科技(上海)股份有限公司公布2025年中期业绩。劲方医药科技(上海)股份有限公司公布2025年中期业绩。研发成本为1.2244亿元人民币，较去年同期1.86亿元下降34.2%，主要由于去年同期产生终止中国境外选择权及专利许可协议费用。公司核心产品GFH925(达伯特)已于2024年8月获国家药监局批准上市，成为中国首款及全球第三款获批的KRAS抑制剂。另一核心产品GFH375正在中国进行I/II期临床试验，并已于2025年2月启动II期部分。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250930191626971a3cab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250930191626971a3cab&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02595","BK1515","BK1574","09939"],"gpt_icon":1},{"id":"2571134119","title":"浦东生物医药企业竞逐“全球新”","url":"https://stock-news.laohu8.com/highlight/detail?id=2571134119","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571134119?lang=zh_cn&edition=fundamental","pubTime":"2025-09-30 18:22","pubTimestamp":1759227774,"startTime":"0","endTime":"0","summary":"今年以来，浦东生物医药企业资本市场表现活跃：劲方医药、银诺医药已赴港上市，多家企业密集递交申请。自2018年君实生物成为张江药谷首家港股18A上市企业后，浦东药企赴港上市热潮涌动，产业正从“量变”迈向“质变”。出海方面，今年上半年浦东生物医药企业出海交易近30起，交易额占全国31%、全球14%。据悉，浦东将在2025上海国际生物医药产业周期间，围绕“源头创新 链聚全球”推出更多服务与政策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250930183301954e19e0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250930183301954e19e0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01877","BK1161","BK1515","BK1574","09939","02595","02591"],"gpt_icon":1},{"id":"2571299335","title":"劲方医药-B(02595)分子胶Pan RAS(ON)抑制剂GFH276治疗RAS突变型癌症患者的I/II期临床试验首位患者完成入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2571299335","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571299335?lang=zh_cn&edition=fundamental","pubTime":"2025-09-29 20:40","pubTimestamp":1759149659,"startTime":"0","endTime":"0","summary":"智通财经APP讯，劲方医药-B 发布公告，GFH276治疗RAS突变型晚期实体瘤的I/II期试验首例患者近日已完成入组。目前全球尚无泛RAS靶向药获批上市，GFH276开发进度位于Pan RAS抑制剂赛道的全球前三位。GFH276临床研究的Ia期临床试验将在中山大学肿瘤防治中心、上海复旦大学附属肿瘤医院等约10家研究中心开展。GFH276可靶向抑制多数活化状态的野生╱突变型RAS蛋白。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1350837.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02595","LU1854103824.USD","LU0724618433.USD","LU1861219969.SGD","LU2357305700.SGD","BK1574","LU1978683503.SGD","LU1854104046.USD","LU1720051108.HKD","LU0348723411.USD","BK4512","IE00BD6J9T35.USD","IE00BZ199S13.USD","BK4585","LU2298322129.HKD","LU1861215975.USD","LU1861220033.SGD","LU0124384867.USD","BK4141","LU2360107325.USD","09939","159938","LU1861214812.USD","BK4605","BK4588","BK1515","LU1720051017.SGD","LU1548497426.USD","ON"],"gpt_icon":1},{"id":"2570016202","title":"国信证券-医药生物行业周报（25年第36周）：劲方医药在港交所上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2570016202","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570016202?lang=zh_cn&edition=fundamental","pubTime":"2025-09-25 22:37","pubTimestamp":1758811036,"startTime":"0","endTime":"0","summary":"劲方医药专注RAS相关靶向分子研发，成功在港交所主板上市。劲方医药成立于2017年8月，2025年9月19日在港交所主板上市。公司具有全球视野、全球运营及国内外合作，并已有首款创新药获批上市，聚焦肿瘤、自免和炎症疾病领域研发创新有效的治疗方案。核心产品GFH925与合作伙伴信达生物共同推进研发及商业化，并于2024年8月在国内获批上市，用于治疗2线及以上的KRASG12C突变的NSCLC，成为国内首款、全球第三款获批的KRASG12C选择性抑制剂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025092522394797a97de1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025092522394797a97de1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02595","09939","BK1574","BK1161","BK1515"],"gpt_icon":1},{"id":"2570062064","title":"劲方医药-B09月25日主力净流出839.0万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2570062064","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570062064?lang=zh_cn&edition=fundamental","pubTime":"2025-09-25 16:16","pubTimestamp":1758788167,"startTime":"0","endTime":"0","summary":"09月25日, 劲方医药-B股价跌1.53%，报收40.02元，成交金额1.0亿元，换手率0.78%，振幅6.64%，量比0.00。劲方医药-B今日主力资金净流出839.0万元，上一交易日主力净流入389.6万元。该股近5个交易日上涨96.17%，主力资金累计净流出1846.6万元；近20日主力资金累计净流出1846.6万元，其中净流出天数为3日。该股主力净额占比0.06%，港股市场排名2553/2671。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250925162846a69d2fa0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250925162846a69d2fa0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","09939","BK1515","BK1161","02595"],"gpt_icon":0},{"id":"2569290427","title":"劲方医药涨超11%公司研究数据亮相AACR年会目前已形成RAS靶向疗法矩阵","url":"https://stock-news.laohu8.com/highlight/detail?id=2569290427","media":"动脉网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569290427?lang=zh_cn&edition=fundamental","pubTime":"2025-09-24 11:01","pubTimestamp":1758682860,"startTime":"0","endTime":"0","summary":"劲方医药-B(02595)股价涨超11%，截至发稿涨10.67%，报43.78港元。此前在美国癌症研究协会(AACR)年会上，劲方医药三款大、小分子产品(GFH276、GFS202A、GFH375)临床前研究入选年会壁报环节，研发进度领先，靶向多个大适应症，展现其管线创新与丰富。国投证券指出，劲方医药为全球布局的创新药企，聚焦肿瘤、免疫疾病领域，已形成RAS靶向疗法矩阵，并积极拓展其他“全球新”靶向药及新疗法管线，已布局KRAS G12C、KRAS G12D等多个靶点分子，其中核心产品KRAS G12D抑制剂GFH375已在胰腺癌、NSCLC等领域取得积极数据，后续临床进展值得关注。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025092411261295417f29&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025092411261295417f29&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09939","BK1515","BK1574","BK1161","02595"],"gpt_icon":0},{"id":"1119429987","title":"异动解读 | 劲方医药-B盘中大涨10.92%，股东转仓4.37亿港元或提振信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1119429987","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119429987?lang=zh_cn&edition=fundamental","pubTime":"2025-09-24 10:34","pubTimestamp":1758681281,"startTime":"0","endTime":"0","summary":"劲方医药-B今日盘中大涨10.92%，引起市场广泛关注。该股近期表现强劲，投资者情绪高涨。消息面上，香港联交所最新资料显示，9月23日，劲方医药-B股东将价值4.37亿港元的股票由中信证券经纪香港转入渣打银行（香港），占公司股份的3.42%。值得注意的是，劲方医药-B于9月19日在港交所首次公开招股，上市首日表现亮眼，盘中最高涨幅达146.20%，收盘大涨106.47%，市值接近150亿港元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02595"],"gpt_icon":0},{"id":"2569747788","title":"劲方医药-B(02595)股东将股票由中信证券经纪香港转入渣打银行(香港) 转仓市值4.37亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2569747788","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569747788?lang=zh_cn&edition=fundamental","pubTime":"2025-09-24 08:23","pubTimestamp":1758673417,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，9月23日，劲方医药-B(02595)股东将股票由中信证券经纪香港转入渣打银行(香港)，转仓市值4.37亿港元，占比3.42%。9月19日，劲方医药-B在港交所首挂上市，盘中股价一度达到50.20港元，较发行价提升146.20%，并最终收涨106.47%，市值直逼150亿港元。公开资料显示，劲方医药专注于肿瘤(涵盖多种实体瘤的不同治疗线)以及自体免疫和炎症性疾病领域的新治疗方案开发，已建立起一条产品管线，包括8款候选产品，其中5款处于临床开发阶段，包括两款核心产品GFH925和GFH375。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1348722.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1655091616.SGD","BK1574","LU1064130708.USD","BK1521","600030","LU2148510915.USD","159938","LU1997244956.HKD","BK0183","LU1328615791.USD","LU1794554557.SGD","LU0405327148.USD","LU1064131003.USD","LU1997245177.USD","09939","BK1161","06030","BK1564","BK0028","LU1720050803.USD","BK0188","BK0012","02595","LU1997245094.SGD","LU2495084118.USD","LU2289578879.USD","BK1516","LU0405327494.USD","BK0276","BK0196","BK1147","LU1255011170.USD","BK1515"],"gpt_icon":0},{"id":"2569076691","title":"一图解码：港股IPO一周回顾 11家公司递表 劲方医药上市后股价震荡","url":"https://stock-news.laohu8.com/highlight/detail?id=2569076691","media":"IPO解码","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569076691?lang=zh_cn&edition=fundamental","pubTime":"2025-09-23 11:48","pubTimestamp":1758599339,"startTime":"0","endTime":"0","summary":"过去一周，港股IPO市场共有11家公司递交上市申请，包括中润光能、暖哇洞察、华勤技术、若羽臣和量化派等；2家公司通过了港交所聆讯，分别为西普尼和轩竹生物；而西普尼在通过聆讯4天后就启动招股，除此之外上周启动招股的新公司还有不同集团、奇瑞汽车和紫金黄金国际；3家公司正式挂牌上市，分别为禾赛、健康160和劲方医药。其中，劲方医药于2025年9月19日正式登陆港交所。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250923124156a43dd51e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250923124156a43dd51e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02595","BK1161","BK1574","HSTECH","BK1515","09939","HSCEI"],"gpt_icon":1},{"id":"2569789086","title":"上市次日跌逾6%仍获“惜售”，劲方医药-B(02595)何以成创新药牛市“新宠”？","url":"https://stock-news.laohu8.com/highlight/detail?id=2569789086","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569789086?lang=zh_cn&edition=fundamental","pubTime":"2025-09-22 19:29","pubTimestamp":1758540549,"startTime":"0","endTime":"0","summary":"劲方医药的上市首日成绩，实际上就是本轮港股创新药牛市的又一具象化体现。今年政府工作报告首次明确提出“健全药品价格形成机制，制定创新药目录，支持创新药和医疗器械发展”。但在9月22日，劲方医药在收跌6.13%的情况下，场内出现明显“惜售”，当日成交量从上市首日的3491.35万股断崖跌至473.66万股。也就是说，绝大多数投资者仍选择继续持有，“惜售”态度占据上风。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1348075.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159992","BK1161","02595","BK1515","BK1574","06978","09939","159938"],"gpt_icon":1},{"id":"2569781861","title":"9月14-20日港股IPO观察：11家递表、3家上市，奇瑞汽车募资火爆","url":"https://stock-news.laohu8.com/highlight/detail?id=2569781861","media":"上市公司网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569781861?lang=zh_cn&edition=fundamental","pubTime":"2025-09-22 18:13","pubTimestamp":1758535983,"startTime":"0","endTime":"0","summary":"中国上市公司网据统计，9月14日至9月20日期间，港股市场共有11家公司提交招股书，2家公司通过聆讯。此外，有4家公司正在进行招股，3只新股成功上市。3)、9月15日，中润光能第二次向港交所递交招股书，拟在香港主板上市，联席保荐人分别为中信建设国际、中信证券。7)、9月16日，华勤技术首次向港交所递交招股书，拟在香港主板上市，独家保荐人为信达国际。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250922193025a72f4d7d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250922193025a72f4d7d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02259","02595","02656","06090","09973","HSTECH","HSCEI"],"gpt_icon":1},{"id":"2569078126","title":"近期国内融资|劲方医药港股上市，爱科百发和新元素医院IPO申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2569078126","media":"药菓","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569078126?lang=zh_cn&edition=fundamental","pubTime":"2025-09-22 18:00","pubTimestamp":1758535223,"startTime":"0","endTime":"0","summary":"公司核心产品3D细胞微载体为国内首款可用于细胞药物开发的药用辅料级微载体。03爱科百发递表港交所9月15日拟上市公司：上海爱科百发生物医药技术股份有限公司公司主页：https://www.arkbiosciences.com/拟上市交易所：港交所保荐人：摩根大通和中信证券爱科百发成立于2013年，专注于解决呼吸系统和儿科疾病的医疗需求，已开发六种候选药物管线。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250922195917a43c6109&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250922195917a43c6109&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09939","BK1515","BK1574","BK1161","02595"],"gpt_icon":1},{"id":"2569204045","title":"劲方医药-B09月22日主力净流出40.0万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2569204045","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569204045?lang=zh_cn&edition=fundamental","pubTime":"2025-09-22 16:15","pubTimestamp":1758528929,"startTime":"0","endTime":"0","summary":"09月22日, 劲方医药-B股价跌6.65%，报收39.30元，成交金额1.9亿元，换手率1.46%，振幅8.69%，量比0.00。该股近5个交易日上涨93.62%，主力资金累计净流出40.0万元；近20日主力资金累计净流出40.0万元，其中净流出天数为1日。|09月22日主力加仓幅度排名||#|股票简称|主力净额占比|#|源想集团|2.79%|#|鹏高控股集团|2.33%|#|声扬集团|2.06%|#|...|...|#2240|劲方医药-B|-0.00%|（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250922161708a43beb09&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250922161708a43beb09&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","09939","BK1161","02595","BK1515"],"gpt_icon":0},{"id":"2569291212","title":"新药周观点：劲方医药IPO上市 KRAS G12D进展值得关注","url":"https://stock-news.laohu8.com/highlight/detail?id=2569291212","media":"国投证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569291212?lang=zh_cn&edition=fundamental","pubTime":"2025-09-21 00:00","pubTimestamp":1758384000,"startTime":"0","endTime":"0","summary":"研发管线方面，公司已布局KRAS G12C、KRAS G12D、泛Ras、CDK9、TGF-βR1、GDF15 / IL-6、RIPK1 等多个靶点的分子。目前公司管线中最值得关注的主要为核心产品KRAS G12D 抑制剂GFH375，其已在胰腺癌、NSCLC 等领域读出多个积极数据，后续临床进展值得关注。本周新药上市申请获批准&受理情况：本周国内有8 个新药或新适应症的上市申请获批准，有12 个新药或新适应症的上市申请获受理。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250921202144953bbaaa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250921202144953bbaaa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02595","BK1574","09939","BK1515","BK1161"],"gpt_icon":1},{"id":"2568218167","title":"被3000亿资金哄抢的创新药企，上市首日暴涨110%","url":"https://stock-news.laohu8.com/highlight/detail?id=2568218167","media":"36氪","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568218167?lang=zh_cn&edition=fundamental","pubTime":"2025-09-20 09:15","pubTimestamp":1758330955,"startTime":"0","endTime":"0","summary":"9月19日，劲方医药在港交所挂牌，首日涨幅接近110%、市值逼近150亿。上市前一日暗盘交易涨幅均超100%，且延续了今年来创新药企业火爆的打新行情，最终申购倍数超过2200倍，金额近3500亿。目前，氟泽雷塞是这家成立7年的创新药公司的首个上市产品，也是国内首个、全球第三款获批上市的KRAS G12C抑制剂。目前，全球范围内已有5款KRAS G12C抑制剂获批，另有20多款产品进入临床开发阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250920093845a72b11cd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250920093845a72b11cd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02595","BK1161","BK1574","06978"],"gpt_icon":1}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":73,"code":"91000000","status":"200"}]}}